Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
ANTIBODY DRUG CONJUGATES THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
PHILADELPHIA, USA
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
ANTIBODY DRUG CONJUGATES THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
PHILADELPHIA, USA
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
ANTIBODY DRUG CONJUGATES THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
PHILADELPHIA, USA
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Michael Tolentino
Co-Founder,
Aviceda Therapeutics
Sessions
26-Jun-2025
16:20 – 17:20
Exploring How Oligonucleotide-Based Immune Modulation Therapies Can Complement Checkpoint Inhibitors And Car-T
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
)
